Bob Englert, Steve Crouse

Vortex Biosciences has appointed Bob Englert as its new CEO. Englert, who was previously the firm's chief technology officer, replaces exiting CEO Gene Walther, who has resigned to pursue other interests and will step down both from his position as CEO and as a member of the company's board.

Englert has over 25 years of experience in medical devices and life sciences, with a particular focus on IVD, point of care, and digital health solutions. Before joining Vortex, he served as CEO and founder of Biomedtrics, a diabetes data management company, and prior to that he was COO of Pelikan Technologies. Earlier in his career, Englert also held multiple senior roles at Abbott Laboratories. He holds a BS in biology from the University of Illinois Urbana-Champaign.

Vortex also said that Steve Crouse, who has been the company's chief commercial officer since March 2016, will now assume the position of chief operating officer. Prior to joining Vortex, Crouse served as senior vice president of sales and marketing at Freeslate, a company focused on providing laboratory automation to chemical and pharmaceutical companies.